Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.38 |
| ▸ | GLRB | P48167 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.30 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412233 | 0.79 | MAP4K4 (0.39) | HPGDSGLRA3GLRBLTA4HHDAC4 | |
| SCHEMBL3940103 | 0.77 | GLRA3 (0.46) | HPGDSGLRA3GLRBLTA4HHDAC4 | |
| SCHEMBL764967 | 0.73 | HPGDS (0.50) | HPGDSLTA4HPIK3CA | |
| SCHEMBL30302065 | 0.73 | HPGDS (0.50) | HPGDSLTA4HPIK3CA | |
| SCHEMBL3846030 | 0.73 | MECP2 (0.51) | HPGDSLTA4H | |
| SCHEMBL29433360 | 0.73 | MECP2 (0.51) | HPGDSLTA4H | |
| SCHEMBL2527622 | 0.72 | GLRA3 (0.68) | GLRA3GLRBLTA4HHDAC4CFTR | |
| SCHEMBL18732095 | 0.72 | LTA4H (0.39) | HPGDSGLRA3GLRBLTA4HHDAC4 | |
| Hydrochloric Acid SCHEMBL30555492 | 0.71 | HPGDS (0.41) | HPGDSGLRA3GLRBLTA4HHDAC4 | |
| SCHEMBL2025419 | 0.71 | LTA4H (0.55) | HPGDSLTA4HHDAC4BRD4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3054955-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054358-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054358-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | AAK1, DAPK2, DAPK1 | HPGDS 2009/4885GLRA3 2647/4885GLRB 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.